Survival projection | Value | Sensitivity range | Source |
---|---|---|---|
Dialysis (probability C2D) | |||
Treatment effect (hazard ratio) | 0.42 | 0.21–0.71 | Bravo-Zúñiga et al. [8] |
Lambdaa | 0.008 | 0.007–0.009 | Estimated |
Gammaa | 0.938 | 0.925–0.952 | Estimated |
Mortality (probability C2Dth) | |||
Treatment effect (hazard ratio) | 1 | 0.88–1.13 | Bravo-Zúñiga et al. [8] |
Lambdaa | 0.043 | 0.034–0.053 | Estimated |
Gammaa | 1.143 | 1.098–1.193 | Estimated |
Mortality among dialysis patients (probability D2Dth) | 0.05 | Cieza-Zevallos et al. [14] | |
Annual costs (USD)b | Estimated (see Table 2) | ||
RHP cost of treatment | 531 | 452–611 | |
Standard of care cost of treatment | 45 | 38–52 | |
Dialysis treatment | 13,459 | 11,440–15,478 | |
RHP Initial investment (one-time) | 30,412 | ||
RHP annual operational costs | 4995 | ||
Utility scores | Go et al. [16] | ||
CKD event-free | 0.84 | 0.76–0.92 | |
First time dialysis | 0.65 | 0.59–0.72 | |
General | |||
Discount rate costs and outcomes (%) | 3 | 0–5 | |
Exchange rate (PEN per USD) | 3.3 | Central Reserve Bank of Peru [17] | |
Projection length (cycles) | 30 | ||
Cycle length (years) | 1 |